Chiusura precedente | 2,6800 |
Aperto | 2,6125 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 2,5400 - 2,6400 |
Intervallo di 52 settimane | 2,0600 - 5,5900 |
Volume | |
Media Volume | 8.998 |
Capitalizzazione | 14,746M |
Beta (5 anni mensile) | 0,70 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,7200 |
Prossima data utili | 07 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | 0,28 (10,59%) |
Data ex dividendo | 24 mag 2023 |
Stima target 1A | N/D |
ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to h
ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards wer
ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,0